Peripheral Vascular Disease (PVD) — HCC Risk Adjustment Focus — Clinical Documentation Guide (2026)

This guide focuses on Peripheral Vascular Disease (PVD) within the Medicare Advantage risk adjustment (HCC v28) context, with deep CDI query templates and RADV audit preparation. For a comprehensive clinical overview of PVD including pathophysiology, diagnostics, and full procedural coding, see the companion PVD Clinical Documentation Guide.

🔍 Definition

Peripheral Vascular Disease (PVD) is a broad term encompassing circulatory disorders affecting blood vessels outside the heart and brain — most commonly atherosclerotic narrowing or occlusion of the peripheral arteries supplying the lower and upper extremities. In the risk adjustment context, PVD coding specificity is critical: the difference between an unspecified PVD code and a highly specific atherosclerosis-with-gangrene code can represent hundreds of dollars per member per month in CMS Medicare Advantage risk adjustment payments.

Under CMS-HCC Model V28 (100% operative as of January 1, 2026), PVD conditions distribute across two primary HCC categories with distinct relative factor (RF) weights:

• HCC 263 — Atherosclerosis of Arteries of the Extremities with Ulceration or Gangrene: RF 1.118 (community, non-dual, aged)
• HCC 264 — Vascular Disease with Complications (includes atherosclerosis with rest pain, thrombosis, embolism): RF 0.455

Crucially, intermittent claudication alone (I70.211–I70.219) no longer maps to a payment HCC under V28, representing a significant shift from V24 where it contributed to HCC 107. Capturing the highest clinically supported specificity — rest pain, ulceration, or gangrene — is now essential to secure RAF credit for the documented disease burden.

🗂️ Alternative Terminology

🩺 Signs & Symptoms

Symptom severity corresponds directly to the appropriate ICD-10-CM code and HCC category. AHA research confirms ICD-10 codes accurately distinguish claudication versus CLTI with 81% sensitivity and 82% specificity when documentation is specific.

• Intermittent claudication — cramping, aching, or fatigue in calf, thigh, or buttock with exertion; resolves with rest. Corresponds to I70.21x. Note: no RAF credit in V28 alone.
• Rest pain — persistent burning or aching pain in foot or toes at rest, especially nocturnal; relieved by dependency. Corresponds to I70.22x (HCC 264, RF 0.455).
• Non-healing ulceration — ischemic ulcer at pressure points, toes, or heel; punched-out appearance, pale base, minimal bleeding. Corresponds to I70.23x–I70.25x (HCC 263, RF 1.118).
• Gangrene — dry or wet necrosis, blackened digits or foot. Corresponds to I70.26x (HCC 263, RF 1.118).
• Diminished or absent pedal pulses, bruits over femoral/popliteal arteries
• Dependent rubor, pallor on elevation, prolonged capillary refill
• Hair loss on lower extremity, shiny atrophic skin, muscle atrophy
• Ankle-Brachial Index (ABI): >1.4 non-compressible (media calcification), 0.9–1.4 normal, 0.70–0.89 mild PAD, 0.40–0.69 moderate PAD, <0.40 severe PAD/CLTI

🧭 Differential Diagnosis

📋 Clinical Indicators for Coders/CDI

Clinical indicators that should trigger CDI review and potential code specificity escalation in PVD cases:

🦴 Anatomy & Pathophysiology

PVD in the risk adjustment context is primarily driven by atherosclerosis of the peripheral arteries — a chronic, progressive inflammatory disease in which cholesterol plaques accumulate in the intima of medium and large vessels, progressively narrowing the lumen and reducing perfusion to distal tissues.

Vascular territory affected — ICD-10-CM I70.2xx governs atherosclerosis of native arteries of the extremities. The aortoiliac segment (Leriche syndrome), femoral-popliteal segment, and tibial/peroneal arteries each carry distinct procedural and documentation implications. I70.3xx–I70.7xx govern bypass graft disease (autologous vein, nonautologous biological, nonbiological, other).

Disease progression spectrum (Fontaine Classification → ICD-10-CM mapping):

• Stage I — Asymptomatic: ABI <0.9 without symptoms. Coded as I70.209 (atherosclerosis of native arteries, unspecified extremity, no ulceration/rest pain). No V28 RAF.
• Stage IIa/IIb — Claudication: I70.211–I70.219. No V28 RAF.
• Stage III — Rest pain (CLTI, formerly CLI): I70.221–I70.229. HCC 264, RF 0.455.
• Stage IV — Tissue loss (ulceration/gangrene) (CLTI): I70.231–I70.269. HCC 263, RF 1.118.

Pathophysiology of CLTI / Critical Limb Ischemia — Chronic Limb-Threatening Ischemia (CLTI) represents the severe end of the PAD spectrum, characterized by inadequate perfusion to sustain tissue viability at rest. As of ICD-10-CM FY2020+ and confirmed for FY2026, CLTI and Critical Limb Ischemia (CLI) are recognized as equivalent terms, indexed directly to the I70 category codes involving rest pain, ulceration, and gangrene.

Diabetic macroangiopathy — In diabetic patients, accelerated atherosclerosis affects tibial and peroneal vessels disproportionately, often producing CLTI without proximal disease. The coding pathway differs: E11.51 (diabetic peripheral angiopathy without gangrene) or E11.52 (with gangrene) captures the diabetes-attributable vascular damage. Additional I70.2xx codes may be coded separately per ICD-10-CM guidelines.

💊 Medication Impact / Treatment

Medications relevant to PVD affect both documentation and coding:

• Antiplatelet therapy — Aspirin, clopidogrel (Plavix), ticagrelor; first-line for symptomatic PAD per AHA/ACC PAD Guidelines; code long-term use Z79.82 (long-term use of aspirin), Z79.02 (long-term use of antithrombotics)
• Statins — Atorvastatin, rosuvastatin; mandatory in PAD for plaque stabilization; code long-term use Z79.899
• Cilostazol (Pletal) — Phosphodiesterase inhibitor; improves claudication distance; specific to claudication symptom management
• Vorapaxar (Zontivity) — PAR-1 antagonist; reduces MACE in established PAD
• Rivaroxaban (Vascular dose Xarelto) — COMPASS trial regimen (2.5 mg BID + aspirin) for high-risk PAD; code Z79.01 (long-term anticoagulant use)
• Antihypertensives / ACE inhibitors — HOPE trial data support ACE inhibition in PAD even without hypertension
• Wound care medications — In CLTI: topical antimicrobials, growth factors, negative pressure wound therapy (NPWT); document wound grade per WIfI classification
• Insulin / oral antidiabetics — In diabetic PVD: code Z79.4 (long-term insulin use) or Z79.84 (long-term use of oral hypoglycemic drugs); critical for E11.5x combo coding

Preview ends here. The full guide continues with FY2026 ICD-10-CM code sets, CPT surgical coding, MS-DRG mapping, reimbursement guidance, CDI query templates, and an audit checklist — all available to CCO Members.

← Back to All Clinical Documentation Guides